{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:46:09Z","timestamp":1790721969130,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp;amp; Perspec"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Over the last few years, fluoxetine has been one of the most prescribed medications for the treatment of diverse psychiatric conditions in Mexico. Fluoxetine therapeutic effect is consequence of the joint action of the parent drug and its active metabolite, norfluoxetine. However, the clinical efficacy of fluoxetine, can be affected due to diverse factors, such as drug\u2010drug interactions and the large interindividual variability in the pharmacokinetics of this drug. The aim of this study was to determine the factors associated with variability in plasma concentrations of fluoxetine and norfluoxetine and its association with the therapeutic response. Fluoxetine and norfluoxetine plasma concentrations were quantified by liquid chromatography in 81 Mexican patients with mental disorders; 25% of the patients had no medication adherence and 40% were below the reference range of fluoxetine plus norfluoxetine plasma concentrations. The results showed that concentrations can be affected by fluoxetine metabolism caused by CYP2D6 phenotype and the concomitant administration of olanzapine. Furthermore, CYP3A5 and CYP2C19 phenotype were associated with lower anxiety and depression control during treatment with fluoxetine. This study can be a starting point to elucidate the causes of fluoxetine variable response in Mexican patients with mental disorders, as well as to detect and support medication adherence.<\/jats:p>","DOI":"10.1002\/prp2.864","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T02:16:33Z","timestamp":1631672193000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-3495","authenticated-orcid":false,"given":"Julia","family":"Sagah\u00f3n\u2010Az\u00faa","sequence":"first","affiliation":[{"name":"Department of Pharmacy Faculty of Chemical Sciences Autonomous University of San Luis Potos\u00ed San Luis Potos\u00ed M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna Edith","family":"Medell\u00edn\u2010Garibay","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Faculty of Chemical Sciences Autonomous University of San Luis Potos\u00ed San Luis Potos\u00ed M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya Eloisa","family":"Ch\u00e1vez\u2010Castillo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Faculty of Chemical Sciences Autonomous University of San Luis Potos\u00ed San Luis Potos\u00ed M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar Guillermo","family":"Gonz\u00e1lez\u2010Salinas","sequence":"additional","affiliation":[{"name":"Psychiatric Service Central Hospital \u201cDr. Ignacio Morones Prieto\u201d San Luis Potos\u00ed M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-8184","authenticated-orcid":false,"given":"Rosa del Carmen","family":"Mil\u00e1n\u2010Segovia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Faculty of Chemical Sciences Autonomous University of San Luis Potos\u00ed San Luis Potos\u00ed M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Romano\u2010Moreno","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Faculty of Chemical Sciences Autonomous University of San Luis Potos\u00ed San Luis Potos\u00ed M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2017.10.002"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.147"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1021\/cn400186j"},{"key":"e_1_2_9_5_1","unstructured":"CoEL.Medication Guide Reference ID: 4074888.2009. Food and Drug Administration. Accessed December 10 2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018936s103 021235s023lbl.pdf"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2014.907790"},{"key":"e_1_2_9_7_1","unstructured":"World Health Organization.The global burden of disease: 2004 update.2008. Accessed December 9 2020.https:\/\/www.who.int\/healthinfo\/global_burden_disease\/2004_report_update\/en\/"},{"key":"e_1_2_9_8_1","unstructured":"INCYTU Salud mental en M\u00e9xico O.d.i.c.y.t.p.e.c.d.l. Uni\u00f3n Editor. Accessed December 9 2020.https:\/\/www.foroconsultivo.org.mx\/INCyTU\/documentos\/Completa\/INCYTU_18\u2010007.pdf"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.8.1371"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.50"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.02.063"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-014-0210-9"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13492"},{"issue":"1","key":"e_1_2_9_14_1","first-page":"28","article-title":"Determination of drugs in plasma samples by high\u2010performance liquid chromatography\u2010tandem mass spectrometry for therapeutic drug monitoring of schizophrenic patients","volume":"40","author":"Domingues DS","year":"2016","journal-title":"J Anal Toxicol"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.23"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-116492"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328351d47f"},{"issue":"4","key":"e_1_2_9_18_1","first-page":"1","article-title":"Prevalencia de trastornos mentales y uso de servicios: resultados de la Encuesta Nacional de Epidemiolog\u00eda Psiqui\u00e1trica en M\u00e9xico","volume":"26","author":"Medina\u2010Mora ME","year":"2003","journal-title":"Salud Mental"},{"key":"e_1_2_9_19_1","unstructured":"Secretar\u00eda de Salud M\u00e9xico.Informe de la evaluaci\u00f3n del sistema de salud mental en M\u00e9xico utilizando el Instrumento de Evaluaci\u00f3n para Sistemas de Salud Mental de la Organizaci\u00f3n Mundial de la Salud (IESM\u2010OMS) Secretar\u00eda de Salud M\u00e9xico.2011. Accessed December 10 2020.https:\/\/www.who.int\/mental_health\/who_aims_country_reports\/who_aims_report_mexico_es.pdf"},{"key":"e_1_2_9_20_1","unstructured":"Organizaci\u00f3n Panamericana de la Salud.Depresi\u00f3n y otros trastornos mentales comunes. Estimaciones sanitarias mundiales. Washington D.C. Licencia: CC BY\u2010NC\u2010SA 3.0 IGO.2017. Accessed December 15 2020.https:\/\/www.paho.org\/es\/documentos\/depresion\u2010otros\u2010trastornos\u2010mentales\u2010comunes\u2010estimaciones\u2010sanitarias\u2010mundiales"},{"key":"e_1_2_9_21_1","unstructured":"CoEL.Application number: 18\u2010936\/S\u2010054 Prozac FDA Final Printed Label.1999. Accessed December 15 2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/18\u2010936S054_Prozac_Prntlbl.pdf"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.01.001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/526837"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04134.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004216"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00027.2017"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6040106"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12816"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.97"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15454"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.05.020"},{"issue":"6","key":"e_1_2_9_33_1","first-page":"828","article-title":"Aldosterone: new knowledge on its morphological\u2010functional aspects","volume":"15","author":"Garc\u00eda Cabrera L","year":"2011","journal-title":"MEDISAN"},{"issue":"4","key":"e_1_2_9_34_1","article-title":"Antidepressants for the treatment of people with co\u2010occurring depression and alcohol dependence","volume":"4","author":"Agabio R","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.09.031"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-015-9457-6"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000506"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.06.009"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2001.00174.x"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-012-0305-6"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.12"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.864","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.864","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:38:03Z","timestamp":1784810283000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/prp2.864"],"URL":"https:\/\/doi.org\/10.1002\/prp2.864","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"2021-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00864"}}